title: Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
abstract: Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus that has caused severe epidemics in Africa and Asia and occasionally in Europe. As of today, there is no licensed vaccine available to prevent CHIKV infection. Here we describe the development and evaluation of novel CHIKV vaccine candidates that were attenuated by deleting a large part of the gene encoding nsP3 or the entire gene encoding 6K and were administered as viral particles or infectious genomes launched by DNA. The resulting attenuated mutants were genetically stable and elicited high magnitudes of binding and neutralizing antibodies as well as strong T cell responses after a single immunization in C57BL/6 mice. Subsequent challenge with a high dose of CHIKV demonstrated that the induced antibody responses protected the animals from viremia and joint swelling. The protective antibody response was long-lived, and a second homologous immunization further enhanced immune responses. In summary, this report demonstrates a straightforward means of constructing stable and efficient attenuated CHIKV vaccine candidates that can be administered either as viral particles or as infectious genomes launched by DNA.
  
  
  OBJECTIVE
  Similar to other infectious diseases, the best means of preventing CHIKV infection would be by vaccination using an attenuated vaccine platform which preferably raises protective immunity after a single immunization. However, the attenuated CHIKV vaccine candidates developed to date rely on a small number of attenuating point mutations and are at risk of being unstable or even sensitive to reversion. We report here the construction and preclinical evaluation of novel CHIKV vaccine candidates that have been attenuated by introducing large deletions. The resulting mutants proved to be genetically stable, attenuated, highly immunogenic, and able to confer durable immunity after a single immunization. Moreover, these mutants can be administered either as viral particles or as DNA-launched infectious genomes, enabling evaluation of the most feasible vaccine modality for a certain setting. These CHIKV mutants could represent stable and efficient vaccine candidates against CHIKV.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: David
authors.initials: D
authors.lastname: Hallengärd
authors.forename: Maria
authors.initials: M
authors.lastname: Kakoulidou
authors.forename: Aleksei
authors.initials: A
authors.lastname: Lulla
authors.forename: Beate M
authors.initials: BM
authors.lastname: Kümmerer
authors.forename: Daniel X
authors.initials: DX
authors.lastname: Johansson
authors.forename: Margit
authors.initials: M
authors.lastname: Mutso
authors.forename: Valeria
authors.initials: V
authors.lastname: Lulla
authors.forename: John K
authors.initials: JK
authors.lastname: Fazakerley
authors.forename: Pierre
authors.initials: P
authors.lastname: Roques
authors.forename: Roger
authors.initials: R
authors.lastname: Le Grand
authors.forename: Andres
authors.initials: A
authors.lastname: Merits
authors.forename: Peter
authors.initials: P
authors.lastname: Liljeström
mesh_terms: D018354:Alphavirus Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D065632:Chikungunya Fever; D002646:Chikungunya virus / Q000235:genetics / Q000276:immunology*; D005260:Female; D023061:Gene Order; D016679:Genome, Viral; D007111:Immunity, Cellular; D007114:Immunization; D007117:Immunization, Secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014764:Viral Proteins; D014765:Viral Vaccines